MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Relmada Therapeutics Company Profile (NASDAQ:RLMDD)

Consensus Ratings for Relmada Therapeutics (NASDAQ:RLMDD) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.00 (48.31% upside)

Analysts' Ratings History for Relmada Therapeutics (NASDAQ:RLMDD)
Show:
DateFirmActionRatingPrice TargetActions
9/3/2015FBR & Co.Initiated CoverageMarket Perform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Relmada Therapeutics (NASDAQ:RLMDD)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Relmada Therapeutics (NASDAQ:RLMDD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Relmada Therapeutics (NASDAQ:RLMDD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Relmada Therapeutics (NASDAQ:RLMDD)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Relmada Therapeutics (NASDAQ:RLMDD)
DateHeadline
06/25/16 09:52 AMRelmada Therapeutics Inc (OTCMKTS:RLMD) Slips Again
06/09/16 09:08 AMRelmada Therapeutics' d-Methadone gets US FDA orphan drug status for management of PHN
04/14/16 09:10 AMAnalysts' Downgrades for April, 14th (DLAR, IWSY, JOB, JRVR, JTPY, JYNT, KHNGY, KNL, LBRDA, LC) - Washington News Wire - Analysts' Downgrades for April, 14th (DLAR, IWSY, JOB, JRVR, JTPY, JYNT, KHNGY, KNL, LBRDA, LC)Washington News WireRelmada Therapeutics (NASDAQ:RLMDD) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company.and more »
09/09/15 07:00 AMRelmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL™ - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids - [PR Newswire] - NEW YORK, Sept. 9, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that U.S. Patent ...
09/02/15 07:00 AMRelmada Therapeutics to Participate in Two Upcoming Investor Conferences - [PR Newswire] - NEW YORK, Sept. 2, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the ...
About Relmada Therapeutics

Relmada Therapeutics logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RLMDD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.72
  • 50 Day Moving Average: $3.11
  • 200 Day Moving Average: $5.64
  • P/E Ratio: 9.22
  • P/E Growth: 0.00
  • Market Cap: $56.64M
  • Current Quarter EPS Consensus Estimate: $-1.40 EPS
Additional Links:
Relmada Therapeutics (NASDAQ:RLMDD) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha